News | August 16, 2022
QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Man lost 54 Kgs in 6 months with MGB procedure
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
The product will be manufactured at Lupin’s facility in Goa, India.
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years
Subscribe To Our Newsletter & Stay Updated
